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Background. Colorectal carcinomas (CRC) from the serrated route like serrated 
adenocarcinoma and CC showing molecular features of microsatellite instability 
(hmMSI-H) share common features (preference for female genre, right side location, 
mucinous histology and altered CpG methylation patterns) but dramatically differ in 
terms of prognosis, development of immune response and treatment options. Despite 
this fact, to date no expression profiling comparison was carried out to find out which 
functions and genes may be responsible for such differences. Methods. The molecular 
signatures of SAC and hmMSI-H were obtained with transcriptomic arrays and qPCR 
and immunohistochemistry (IHC) were used to validate differentially expressed genes 
at mRNA and protein level. Results. An over-representation of innate immunity 
functions (granulomonocytic recruitment, chemokine production, TLR signaling, 
antigen processing and presentation) were obtained from this comparison and ICAM1 
was more expressed in hmMSI-H whereas two genes (CRCP and CXCL14) were more 
expressed in SAC. These array results were subsequently validated by qPCR and 
CXCL14 and ICAM1 by IHC. Conclusions. Our findings point out specific functions 
and genes which provide a better understanding about the role of immune response in 
serrated pathological route and may be of help for identifying particular molecular 








The so-called adenoma-carcinoma sequence is typically characterized by chromosomal 
instability and microsatellite stability (MSS) and by ending up in the development of 
conventional carcinoma (CC) [Vogelstein]. Less is known about the CRCs being the 
end-point of the serrated pathway although high-level of microsatellite instability (MSI-
H), BRAF mutation and CpG island methylation phenotype (CIMP) seems to be driven 
forces in this carcinogenic process [Makinen, 26]. ]. Based on common features as right 
sided location and the identification of remnants of serrated polyps (SP) adjacent to the 
tumor, it was assumed that serrated adenocarcinoma (SAC) and CRC showing 
histological and molecular features of MSI-H [10] (hMSI-H) are both end-points of the 
serrated pathway [108]. Strikingly, SAC and hMSI-H differ in terms of prognosis, and 
treatment options. SAC has been recognized in the latest WHO classification of tumors 
of the digestive system as a new subtype of colorectal cancer (CRC)[1], accounting for 
7.5 to 8.7% of all CRCs[2,3]. Criteria for its histologic diagnosis have been proposed 
[2] and validated in a series of 81 cases [3] and it has been shown to have a worse 
prognosis than conventional carcinoma (CC) [3] displaying a higher frequency of 
adverse histological features at the invasive front including a weak peritumoral 
lymphocyte response [4]. On the contrary, hMSI-H is characterized by the occurrence of 
Crohn-like reaction and peri- and intra-tumoral infiltrates [10]. Moreover, it has been 
recently demonstrated that, based on higher expression of PD-L1 and BRAF mutation, 
hMSI-H patients are candidates for immune checkpoint and tyrosine kinase inhibitors, 
respectively [95,96]. In contrast, the frequency of KRAS mutation in SAC is even high 
than in CC [12, 13] and SAC display mostly MSS thus making them refractory to anti-
EGFR monoclonal antibodies and immune checkpoint inhibitors. For these reasons, the 
aim of this work is, by using molecular profiling, to ascertain which molecular features 
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are responsible for such differences in immune response between SAC and hMSI-H 
with a view to identify useful diagnostic biomarkers. 
 
Material and Methods 
Patients and tumor samples 
The clinico-pathological features of the patients have been previously reported.[3,4] and 
approval for the study was granted by the Local Ethical Board. SACs were diagnosed 
on the basis of criteria proposed by Mäkinen et al.[2] and hMSI-Hs according to prior 
established criteria (mucinous, signet-ring cell, and medullary carcinoma, tumor 
infiltrating and peritumoral lymphocytes, “Crohn-like” inflammatory response, poor 
differentiation, tumor heterogeneity, and “pushing” tumor border).[10] Frozen samples 
of 11 SACs and four hMSI-H were retrieved from the Santa Lucia University Hospital, 
Cartagena, Spain and used for the gene expression microarray study. Validation by 
qPCR was performed upon frozen specimens of 12 SAC and nine hMSI-H and, in 
addition, adjacent normal mucosa was also analyzed from seven SACs and six hMSI-H. 
Paraffin blocks of 10 SAC and 15 matched hMSI-H, included in previous works, [8,13] 
were used for immunohistochemistry (IHC) validation. Clinico-pathological features of 
the study cases are shown in Table 1. The study was approved by the Hospital Ethics 
Committee and was carried out in accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki and its later amendments. Written informed consent was 






A volume of approximately 10mm3 was extracted from each frozen tissue using the 
disposable sterile biopsy punch Acupunch 2mm (AcudermInc, Lauderdale, FL, USA). 
RNA was extracted following the manufacturer´s instructions (Qiagen, Hilden, 
Germany). Briefly, tissue was disrupted and homogenized in 700µl of Qiazol (Qiagen 
ref:1023537) using a Tissueruptor by Qiagen for 20 seconds. The homogenate was 
incubated at room temperature for 5 minutes. After adding 140µl of chloroform and 
centrifuging at 12,000xg for 15 minutes at 4ºC, 350µl of the aqueous phase was 
subjected to automatic total RNA extraction using the Qiacube equipment and the 
miRNeasy Mini Kit (ref:217004), both provided by Qiagen.  
 
RNA labelling and microarray hybridisation  
Total RNA was quantified by spectrometry (NanoDrop ND1000, NanoDrop 
Technologies, Wilminton, Delaware USA) and fragment size distribution was analysed 
by RNA 6000 Pico Bioanalyzer assay (Agilent Technologies, Palo Alto, California 
USA). RNA 150ng was concentrated in a SpeedVac to a working dilution and used to 
produce Cyanine 3-CTP-labeled cRNA using the Low Input Quick Amp Labelling Kit, 
One-Color (Agilent p/n 5190-2305) according to the ‘One-Color Microarray-Based 
Gene Expression Analysis’ protocol Version 6.0 (Agilent p/n G4140-90040). This 
method uses T7 RNA polymerase which simultaneously amplifies target material and 
incorporates cyanine 3- labelled CTP. A 2000ng cRNA product was hybridized with 
Whole Human Genome Oligo Microarray Kit (Agilent p/n G2519F-014850) containing 
41,000+ unique human genes and transcripts. Arrays were scanned in an Agilent 
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Microarray Scanner (Agilent G2565BA) according to the manufacturer’s protocol and 
data extracted using Agilent Feature Extraction Software 10.7.1 following the Agilent 
grid template 014850_D_F_20100430 protocol GE1_107_Sep09 and the QC Metric Set 
GE1_QCMT_Sep09. 
 
Microarray data analysis 
Agilent raw data were pre-processed using Agilent background correction and quantile 
normalisation was applied to obtain homogeneous scales in all samples. Differential 
expression analysis was performed on normalized data using the Limma (Linear Models 
for Microarray Data) package by Bioconductor 
(www.bioconductor.org/packages/2.3/bioc/html/limma.html) and comparison was made 
between SAC (n=11) and hMSI-H (n=4). The p-values were corrected by multiple 
testing using the Benjamini and Hochberg method[90] to give adjusted p-values. In 
order to further identify cellular function differences between SAC and hMSI-H, gene 
expression data were analysed by Gene Set Enrichment Analysis (GSA) using the 
FatiScan tool of the Babelomics suite (www.babelomics.org).[91] We used different 
functional annotation databases, namely the pathways from the KEGG database 
(www.genome.jp/kegg) and the Biological Process, Molecular Function and Cellular 
Component from Gene Ontology (GO) (www.geneontology.org). Paintomic 
representations on significant KEGG pathways were used to portray those proteins 
whose gene expression was higher in SAC (blue boxes) or higher in hMSI-H cases (red 
boxes), the intensity of the colour indicating the strength of this difference [92]. 
Differentially expressed GO biological process were represented as scatterplot and 




Quantitative PCR  
The retrotranscriptase reaction was performed from a total of 1 µg of DNAseI-treated 
RNA using the DyNAmo cDNA synthesis Kit (ref:F470L) provided by Thermo 
Scientific (Rockford, IL). Five microlitres of 1:5 diluted cDNA was added to the qPCR 
reaction containing 12.5μl 2X QuantiTect SYBR Green PCR Kit (ref:204145) by 
Qiagen and 300nM of each primer in a total volume of 25μl. qPCR was performed on a 
7500F real time PCR system by Applied Biosystems (Foster City, CA, USA) according 
to the instruction manual and following the standard protocol: 50ºC 2min, 95ºC 10min, 
40 cycles of 95ºC 15sec, 60ºC 1min and a melt curve stage consisting in 95ºC 15sec, 
60ºC min, 95ºC 30sec and 60ºC 30sec. The relative quantitation was done by the 2-ΔCt 
method using β-actin as housekeeping gene. Primers were designed by using primer3 
software and sequences and fragment size are described in Table 2. 
 
Immunohistochemistry 
The validation subset consisted of 40 SC and 20 hMSI-H cases matched for gender, age, 
location. Blocks from each case were selected based on larger tumor invasive front 
areas and all stainings were performed on whole tissue sections using the Benchmark 
Ultra Ventana and the Optiview DAB IHC V5 kit. Details on antibody (purveyor, 
reference, type, (clone); antigen retrieval conditions (buffer, temperature, time); 
incubation (temperature, time) and dilution are as follows: CRCP. Sigma Aldrich, 
HPA007216, polyclonal; CC1, basic, 95ºC, 56min; and room temperature (RT), 
overnight (ON) and 1:350. CXCL14: Abcam, ab3662, polyclonal; C1, basic, 95ºC, 
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56min; RT, ON and 1:100. ICAM1: Cell Signalling Tech, #4915, polyclonal; CC2, 
acid, 95ºC, 48min; RT, ON and 1:300. Endogenous peroxidase activity was blocked 
using 0.5% H2O2 for 5 minutes. For visualization of the antigen, the sections were 
immersed in 3,3'-diaminobenzidine (DAB) and counterstained with Harris´ 
haematoxylin for 5 minutes. As controls, normal liver was used for CRCP, brain for 
CXCL14 and kindney for ICAM1 as suggested by the antibody purveyors. These 
markers were evaluated at the tumor invasive front by considering a staining intensity 
score (1=none or weak staining, 2=moderate, 3=strong) in a given area and a stained 
area score (A< one-third, B=between one- and two-thirds, C> two-thirds). For statistical 
analysis, both intensity and distribution were considered and those immunoscores being 




Statistical analysis was performed using SPSS (Version 15.0, Chicago, IL) package.  
For checking the relationship between mRNA expression by qPCR and histological 
diagnoses the Mann-Whitney’s U test was used. Statistical significance in the 








Differentially expressed functions 
Bioinformatic analysis revealed a considerable number of KEGG pathways and Gene 
Ontology terms differentially expressed in SAC vs. hMSI-H (levels from 3 to 19):  56 
KEGG pathways; 529 GO biological processes (BP); 56 GO cellular component (CC) 
and 101 GO molecular functions (MF). As shown in supplementary material S1, apart 
from differentially represented KEGG pathways dealing with neurodegenerative 
diseases (hsa05014, hsa05012), autoimmune diseases (has04940, hsa05320)  and 
protein and aminoacid metabolism (hsa00270, hsa00280, hsa03050, hsa00310, 
hsa00380) it is remarkable the over-representation of immune response pathways 
(intestinal IgA production (hsa04672, leukocyte transendothelial migration (hsa04670), 
NOD- (hsa04621) and Toll-like receptor signalling (hsa04620), Adipocytokine 
signalling (hsa0920), complement cascade (hsa04610), antigen procession and 
presentation (hsa04612), primary immunodeficiency (hsa05340), Fc epsilon RI 
signaling pathway (hsa04664), B cell receptor signalling pathway (hsa04662), Fc 
gamma R-mediated phagocytosis (hsa04666), allograft rejection (hsa05330), Graft-
versus-host disease (hsa05332). Likewise, differentially expressed GO biological 
processes were related to immune response, such as antigen processing and 
presentation, humoral immunity and cytokine (Fig. 1). More precisely, supplementary 
material S1 points out molecular functions associated with neuropeptide binding, MHC 
and chemokine activities, G-coupled receptors and GTPases, NADH dehydrogenase 
activity and actin binding. Interestingly, when KEGG cytokine-cytokine receptor 
interaction panel was represented with Paintomics, it was observed that the interactions 
of some cytokines (especially chemokines from the C-X-C family) were typical from 
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hMSI-H (CXCL10, CXCL11, IL8, OSM, IL-1B, IFNG and CSF2) whereas in SAC 
almost exclusively involved CXCL14. Other cytokine families such as TGF-β and IL17 
were less differentially implicated in SAC and hmMSI-H (Supplementary material 
S2A). KEGG colorectal cancer panel also showed a dissimilar representation of 
pathways in the comparison of these tumour types whereas the antigen processing and 
presentation panel showed an over-representation in hmMSI-H of molecules 
particularly involved in MHC class I pathway (Supplementary material S2B and S2C, 
respectively). 
 
Differentially expressed genes 
The analysis of microarray data identified 1,144 differentially expressed genes, 533 of 
which were more expressed in SAC than in hmMSI-H and 611 more expressed in 
hmMSI-H. A list of the 34 genes; 17 more expressed in SAC and 17 in hmMSI-H is 
provided as Supplemental material S1. In general terms, genes overexpressed in SAC 
play roles in GTPases signalling and in apoptosis / cell cycle control (GPR56, CRCP, 
PLEKHQ3, TUFT1, FANK1, CDK20, CDK6) whereas those over-represented in 
hmMSI-H were more involved in immune response (LILRA3, CSF3R, CCL3L3, 
ICAM1, FCGR2B, LILRB3, amongst others). Based on the extent of differential 
expression grade, the importance of the biological functions, the design of suitable 
primers and the availability of antibodies we decided to validate CXCL14, CRCP and 
ICAM1 by qPCR and IHC. According to microarray results, CRCP and CXCL14 were 




Validation by qPCR 
Gene expression of CRCP, CXCL14 and ICAM1 was assessed by quantitative PCR in a 
series incorporating more hmMSI-H cases and one more SAC. In order to quantify the 
presence of such genes in normal tissue, healthy mucosa adjacent to tumor was also 
analyzed. As shown in Figure 2, when comparing tumor and normal mucosa, CXCL14 
was more expressed in normal than in tumor tissue (7.35±2.2 vs. 3.63±1.2; p=0.002); 
especially when hmMSI-H tumors were compared to their corresponding adjacent 
mucosa (9.64±4.4 vs. 1.26±0.7; p=0.003). In contrast, ICAM1 was more expressed in 
tumoral than in normal tissue (0.03±0.009 vs. 0.009±0.003; p=0.019), this difference 
being more relevant in hmMSI-H cases where tumor tissues expressed 10 times more 
ICAM1 than neighboring healthy mucosa (0.07±0.03 vs. 0.007±0.003; p=0.003). qPCR 
assays on cancer specimens validated microarray; CRCP and CXCL14 were more 
expressed in SAC than in hmMSI-H (0.22±0.07 vs. 0.04±0.02; p=0.001 and 4.9±1.7 vs. 
1.2±0.7; p=0.003, respectively) whereas ICAM1 was more expressed in hmMSI-H than 
SAC (0.07±0.03 vs. 0.01±0.003; p=0.003).  
 
Validation by immunohistochemistry 
In order to investigate whether differential expressed genes would have an impact on 
protein expression, immunohistochemistry was performed in an extended series. CRCP 
showed a membranous and cytoplasmic staining in normal colorectal epithelial cells 
with no expression on lamina propria cells; CXCL14 was also cytoplasmic and was 
found in neuroendocrine cells from the epithelial crypts in cells from the lamina propria 
whereas ICAM1 expression was absent in colon glands and present in different stromal 
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cells including endothelial cells (Fig 3). CRCP and CXCL14 were also expressed in 
tumor cells whereas ICAM1 was expressed in stromal cells and, stainings were 
evaluated in the corresponding type of cell, accordingly. Results are shown in Table 4 
and representative staining images in Figure 4. CRCP staining was not significantly 
associated with tumor subtype as positive expression was not more frequently observed 
in SAC compared to hmMSI-H (45% vs. 50%; p=0.463). Nevertheless, and in 
agreement with the array results, CXCL14 was more expressed in SAC than in hmMSI-
H (14/40 (35%) vs. 2/20 (20%); p=0.0353) and ICAM1 more expressed in hmMSI-H 
than in SAC (15/20 (75%) vs. 18/40 (45%); p=0.0194.  
 
Discussion 
Despite recent different molecular classifications for colorectal cancer have been 
proposed with a grade of overlap [Guinney, Rodriguez-Salas], CRCs are currently 
diagnosed based their histology [1] and just a few biomarkers are currently used to 
determine the most suitable treatment. It is for this reason important to correlate 
molecular profiling with histological features, this issue being especially critical in the 
serrated pathway for colorectal carcinogenesis since it is not as clearly discerned as the 
conventional adenoma-carcinoma. Furthermore, the immune surveillance awake against 
tumour is now considered as a breakthrough in cancer treatment and in the serrated 
pathological pathway two CRC subtypes can be found with typical weak (SAC) or 
abundant (hMSI-H) immune responses. Therefore, as no previous studies have 
compared the molecular features of serrated pathway CRCs, we aimed to characterize 
the biology of these tumours in order to identify which steps in the complex immune 
response against the tumor could need to be targeted for giving SAC a specific 
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histology-based treatment. With no prior selections of functions our results demonstrate 
that the immune features are what basically make SAC and hMSI-H different at the 
molecular level.  More specifically, activities dealing with innate immunity, antigen 
processing via MHC class I, chemokines from the C-X-C family and transendothelial 
leukocyte migration are more characteristic of hmMSI-H. In fact, the main immune 
response against cancer involved tumour antigen presentation by class I MHC and 
subsequent CD8 T cell activation. Interestingly, amongst most significantly over-
expressed genes in hmMSI-H (Table 3) there is an important representation of those 
coding for proteins involved in carbohydrate ligand binding implicated in immune 
response, such as SIGLEC5 which codes for a cell surface lectin with sialic acid 
recognition sites for the first Ig V set domain [Barb]. In addition, CLEC4D and 
CLEC4A also, over-expressed in hmMSI-H, encode for members of the C-type 
lectin/C-type lectin-like domain (CTL/CTLD) superfamily which have diverse 
functions, such as cell adhesion, cell-cell signalling, binding to carbohydrate 
endogenous and pathogenic ligands, and playing roles in inflammation and immune 
response acting as pattern-recognition and antigen-uptake receptors and also signalling 
cytokine production [Meyer-Wentrup]. A very interesting molecule in immune response 
activated by pathogen carbohydrates and cytokines, such as TNF-α and IL-1, is the 
intercellular cell adhesion molecule-1 (ICAM1 or CD54), a cell surface glycoprotein 
that belongs to the immunoglobulin superfamily (IgSF) of adhesion molecules [101]. 
ICAM1 functions as a co-stimulator on antigen presenting cells, binding to its receptor 
LFA-1 (leukocyte function associated antigen-1) on the surface of T cells during antigen 
presentation [102]. Apical localization of ICAM1 on endothelial cells (or basolateral 
localization on epithelial cells) is a prerequisite for leukocyte trafficking through the 
endothelial (or epithelial) barrier, thus mediating pathogen invasion as well as host 
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defense, a pattern also observed in tumors [101]. Given that in hmMSI-H, the over-
expressed gene ICAM1 is implicated in functions characteristic of this tumor type such 
as antigen processing and presentation, cytokine production and leukocyte 
transendothelial migration, we decided to validate this gene using qPCR and IHC. The 
results confirm at the mRNA and protein levels that ICAM1 is over-expressed in 
hmMSI-H compared to SAC and when comparing tumour versus normal adjacent 
mucosa, ICAM1 was found to be more expressed in tumor than in normal tissue. In 
agreement with our findings, Astarci et al reported, using tumor samples from colon 
cancer patients, that non-transformed normal cells (well-differentiatied) showed no 
immunohistochemical expression of ICAM1, but the poorly differentiated tumor cells 
showed higher expression [Astarci] Moreover, the incidence of lymph node or liver 
metastasis was significantly lower in patients with ICAM1-positive tumors than in those 
with ICAM1-negative tumors, the presence of tumour infiltrating lymphocytes being 
more frequently observed in the ICAM1-positive tumors than in the ICAM1-negative 
tumors. The prognosis of the patients with ICAM1-negative tumors was significantly 
poorer than that of those with ICAM-1-positive tumors [Maeda]. All these findings are 
concordant with ours as hmMSI-H cancer cells are less differentiated than typical gland-
forming SAC cells and develop higher immune response at the tumor 
microenvironment. Other reports have related immunohistochemical ICAM1 expression 
with better prognosis as it was inversely associated with M2 macrophage infiltration 
and with the metastasis index in human colon tumors and that loss of ICAM1 
accelerated liver metastasis of colon carcinoma cells. [Yang]. More specifically, 
ICAM1 downregulation has been associated with immunosuppressant signals; 
Michielsen et al. observed that pre-treatment of monocyte derived dendritic cells with 
tumour conditioned media obtained from colorectal tumour explant culture inhibited the 
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up-regulation of ICAM1 in response to LPS, enhancing IL-10 while reducing IL-12p70 
secretion [Michielsen]. Likewise, it has been demonstrated that mature miR-222 and -
339 suppress ICAM1 expression on tumor cells, thereby down-regulating the 
susceptibility of tumor cells to cytotoxic T lymphocytes (CTL)-mediated cytolysis 
[Ueda] and some other authors showed that the enhanced expression of the 
costimulatory molecules CD40, CD48 and ICAM1 on target cells results in an increased 
state of stimulation of CD8+ T cells, and consequent increased lysis of target cells, this 
effect being mediated mainly through ICAM1 [Slavin-Chiorini]. By studying colorectal 
carcinoma tissue from 96 patients, Maurer et al. concluded that the over-expression of 
ICAM-I might prevent cell-cell disruption and, hence, tumor dissemination, and this 
expression might favor host anti-tumor defense by trafficking of lymphocytes 
[Maurer].Taking together these reports it could be inferred that ICAM1 is an important 
molecule favoring the leukocyte migration to the hmMSI-H microenvironment and 
being able to contribute to an efficient tumor antigen presentation and subsequent 
activation of CTL in this CRC subtype.  
Previous works comparing SAC and CC molecular signatures highlighted that anti-
apoptosis, neural differentiation, cytoskeleton, GTPases, calcium signaling, response to 
hypoxia, tyrosine kinase receptor (TKR)-ERK pathways and the Wnt/β-catenin pathway 
are characteristic activities of SAC [Laiho, Conesa-Zamora IJC, García-Solano IJC, 
Conesa-Zamora Clin Epigen]. Accordingly, amongst the most expressed genes in SAC 
compared to hmMSI-H, some of these functions are also present: apoptosis (FANK1) 
[Wang], neural markers (GTF2IRD2, CRCP, TUFT1), cytoskeleton (MTMR8), GTPases 
(GPR56, PLEKHG3, CRCP), calcium binding (KCNMB3, CRCP), response to hypoxia 
(TUFT1), TKR-ERK signaling (IGFBP2, CDK6, CDK20) and Wnt/β-catenin pathway 
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(AXIN2, FRZB). Given its role as part of a receptor complex for a small neuropeptide, 
its participation in the regulation of GTPase function, in calcium signaling and in the 
granulocytic differentiation, CRCP was chosen to validate the microarray result as 
upregulated in SAC compared to hmMSI-H. According to our results, CRCP might play 
some part in the neoplastic process as it is more expressed in tumor than in normal 
adjacent mucosa. In agreement with the array CRCP was over-expressed in SAC as 
assessed by qPCR. However, we could not validate this finding at the protein level. 
Possible explanation for this fact could be that, as immunohistochemistry does not give 
information on protein functionality or isoform type, nor whether the protein is 
accumulated but not recently expressed nor which of one of the five protein-coding 
transcripts of CRCP is being detected. CRCP is part of a membrane receptor complex 
(CGRP) required for signal transduction at calcitonin gene-related peptide inducing, by 
interacting with GTPases, the activation of protein kinases A and C by increasing 
cAMP and calcium level in the cytosol, respectively and subsequently, activating many 
potential downstream effectors in cells [ Evans]. Previous works have reported a role of 
CRCP in enhancing the formation of granulomonocytic, but not erythroid or mixed, 
colonies by purified human CD34(+) cells [Harzenetter]. This role in granulopoiesis 
might have some consequences in the differentiation of the granulocytic population in 
the tumour microenvironment, thus favoring a tolererogenic immune state. This 
hypothesis deserves future studies like evaluating the effect on proliferation and 
invasion of the reported stable peptide antagonists to CGRP in the tumour milieu 
[Miranda].  
Our array results also pointed out CXCL14 (also known as BRAK) as another 
interesting molecule with implications in the immune regulation. CXCL14 is a 
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chemokine from the C-X-C family which, in contrast to other members of this group, is 
upregulated in SAC compared to hmMSI-H. With the aim of finding some clues of 
whether CXCL14 could have a role in the shift from reactive to tolerogenic immune 
response, we decided to validated it by qPCR and IHC, thus observing an agreement 
with array results using these two techniques. Previous works have associated stromal 
CXCL14, as we evaluated in CRC, with shorter survival in ovarian and breast cancer 
[Zhao, Sjöberg]. Of note, this marker was more expressed in basal-like breast carcinoma 
cases which shares characteristics with SAC such as bad prognosis and Fascin1 over-
expression [Rodríguez-Pinilla, Conesa-Zamora IJC]. Whereas the stromal expression of 
CXCL14 seemed to be associated with worse prognosis, some studies, including the 
transfection of the gene in cancer cell culture, indicated a tumor suppressor role of 
CXCL14 [Lin]. In agreement with our results, Knight et al. observed, using RNAseq, 
that CXCL14 expression in sigmoid and rectum is mainly stromal and not epithelial 
[Knight] and Lin et al. reported that mRNA and protein CXCL14 expression were 
markedly reduced in colorectal carcinoma compared to normal tissues [Lin] as it was 
previously observed for other cancer types [Cao]. Interestingly, CXCL14 is a potent 
chemoattractant for neutrophils, and weaker for dendritic cells, but inactive to 
monocytes, NK cells, and T and B lymphocytes. [Cao]. This cytokine is implicated in 
the homeostasis of monocyte-derived macrophages rather than in inflammation and it 
was reported that a CXCL14-driven recruiting of immature dendritic cells and 
regulatory T cell (Tregs) after a stroke [Lee]. Using recombinant CXCL14, 
Shellenberger et al. showed in vitro, that this chemokine bound immature dendritic cells 
with high affinity and blocked endothelial cell chemotaxis [Shellenberger] thus, 
possibly making difficult the transendothelial migration of immune cells to the tumor 
environment as opposite of ICAM1. In turn, Meuter et al, using a murine model, 
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demonstrated that CXCL14 was dispensable for the homeostatic recruitment of antigen-
presenting cells toward the periphery and for Langerhans cells functionality [Meuter]. 
All these evidences might play an important role in SAC by recruiting 
immunotolerogenic cells, such as Treg and immature dendritic cells, and not those cells 
involved in fighting against the tumor, which are typically NK and T cells, thus 
enabling the immune escape characteristic of this tumor type. Moreover, it has been 
demonstrated that hypoxia inducible factor-1α (HIF-1α) drives CXCL14 expression via 
directly binding to the CXCL14 promoter [Lee] being this evidence particularly relevant 
as upregulation of HIF-1α and response to hypoxia are characteristic of SAC compared 
to conventional colorectal carcinoma [Laiho, Tuomisto, Conesa-Zamora].  
Although it is not yet clear the role of ICAM1, CRCP and CXCL14 in cancer and 
conflicting findings have been reported, it seems that in vivo studies are needed to 
unveil their contribution in the recruitment of granulocytic and monocytic populations 
in the tumor microenvironment and how this impact the immune response against 
colorectal cancer. In conclusion, our study suggests that the dramatic differences of 
SAC and hmMSI-H in terms of immune response against the tumor might be due to 
distinct functions associated with the innate immunity such as endothelial activation, 
granulomonocytic recruitment, antigen presentation via MHC class I and chemokine 
production and this information could be of help for the treatment of SAC, which lacks 
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Table 1. Demographic and pathological features of the study cases. 
  microarray training set qPCR validation set IHC validation set 
  SAC hmMSI-H    SAC hmMSI-H   SAC hmMSI-H   
  n=11 (%) n=4 (%) p-value n=12 (%) n=9 (%) p-value n=40 (%) n=20 (%) 
p-
value 
Gender                   
Female 5 (45.5) 4 (100)   10 (43.5) 7 (77.8)   7 (70) 8 (53.3)   
Male 6 (54.5) 0 (0) 0.029 13 (56.5) 2 (22.2) 0.080 3 (30) 7 (46.7) 0.405 
Age (SD) 65.1[22.4] 61 [22.6] 0.759 68.5 [15.99] 66.4 [15.22] 0.942 71.5 [8.8] 66.3 [14.0] 0.449 
Localization                   
Proximal 9 (81.8) 4 (100)   16 (69.6) 9 (100)   8 (80) 14 (93.3)   
Distal/rectum 2 (18.2) 0 (0) 0.360 7(30.4) 0 (0) 0.061 2 (20) 1 (6.7) 0.315 
Dukes´stage                   
A 3 (27.3) 0 (0)   4 (17.4) 0 (0)   0 (0) 0 (0)   
B 1 (9.1) 2 (50)   4 (17.4) 4 (44.4)   2 (20) 6 (40)   
C 7 (63.6) 2 (50) 0.162 15 (65.2) 5 (55.6) 0.169 8 (80) 9 (60) 0.294 
WHO grade                   
High 1 (9.1) 0 (0)   12 (52.2) 0 (0)   4 (40) 1 (6.7)   
Low 10 (90.9) 4 (100) 0.533 11 (48.8) 9 (100) 0.006 6 (60) 14 (93.3) 0.041 
Type                   
Non-mucinous 7 (63.6) 2 (50)   13 (56.5) 6 (66.7)   8 (80) 12 (80)   
Mucinous 4 (36.4)    2 (50) 0.634 10 (43.5) 3 (33.3) 0.597 2 (20) 3 (20) 1.000 
SAC: Serrated adenocarcinoma; hmMSI-H: Colorectal carcinoma showing molecular and histological 
features of microsatellite instability; qPCR: quantitative polymerase chain reaction. IHC: 














Table 2. Sequences and amplicon sizes for the primers used in this study  
Gene Primer sequence (5´-3´) fragment size (bp) 
CRCP Fw: GCCACAAGTTGACCAAAGCT 97 
  Rv: CCGCTCTTCACTCTCTTCCA   
CXCL14 Fw: CTACAGCGACGTGAAGAAGC 84 
  Rv: ACGCTCTTGGTGGTGATGAT   
ICAM1 Fw: GTGACCGTGAATGTGCTCTC 82 
  Rv: CCTGCAGTGCCCATTATGAC   
B-ACTIN Fw: GAGCTACGAGCTGCCTGACG 122 























Table 3. Selection of the 34 most differentially expressed genes (17 more expressed in 
SAC and 17 in hmMSI-H) as obtained from the array analysis. 
Gene ID Gene description >expressed in  raw.p.value adj.p.value 
FANK1 fibronectin type III and ankyrin repeat domain 1  SAC 7,49E+07 0.0005 
GTF2IRD2 GTF2I repeat domain containing 2 SAC 9,53E+06 0.0006 
MTMR8 myotubularin related protein 8 SAC 9,93E+07 0.0006 
TMEM8B transmembrane protein 8B SAC 1,58E+08 0.0008 
FRZB frizzled related protein SAC 2,37E+08 0.0011 
IYD iodotyrosine deiodinase SAC 2,71E+08 0.0011 
GPR56 adhesion G protein-coupled receptor G1  SAC 3,25E+08 0.0013 
KCNMB3 K+ Ca2+-activated channel subfamily M regulatory β3  SAC 3,36E+08 0.0016 
PLEKHG3 pleckstrin homology and RhoGEF domain containing G3 SAC 4,98E+08 0.0017 
CRCP calcitonin gene-related peptide-receptor component protein SAC 5,25E+06 0.0017 
TUFT1 tuftelin 1 SAC 5,57E+08 0.0018 
ZNF140 zinc finger protein 140  SAC 6,32E+08 0.0019 
CDK20 cyclin dependent kinase 20 SAC 6,35E+08 0.0019 
IGFBP2 insulin like growth factor binding protein 2  SAC 6,84E+08 0.0020 
AXIN2 axin 2 SAC 7,29E+08 0.0020 
CDK6 cyclin dependent kinase 6  SAC 8,09E+06 0.0021 
CXCL14 C-X-C motif chemokine ligand 14 SAC 8,22E+08 0.0021 
GPR109B hydroxycarboxylic acid receptor 3  hmMSI-H 3,04E+07 0.0003 
LILRB3 leukocyte immunoglobulin like receptor B3  hmMSI-H 2,83E+07 0.0003 
CD300A CD300 glycoprotein involved in immune response hmMSI-H 2,78E+07 0.0003 
SLC11A1 solute carrier family 11 member 1 hmMSI-H 2,74E+06 0.0006 
GPR84 G protein-coupled receptor 84 hmMSI-H 2,42E+07 0.0003 
CLEC4D C-type lectin domain family 4 member D  hmMSI-H 2,10E+07 0.0002 
CD14 CD14 molecule involved in innate immune response hmMSI-H 2,07E+07 0.0002 
FCGR2B Fc fragment of IgG receptor IIb hmMSI-H 1,75E+07 0.0002 
CCL3L3 C-C motif chemokine ligand 3 like 3 hmMSI-H 1,72E+07 0.0006 
SOD2 superoxide dismutase 2  hmMSI-H 1,30E+07 0.0002 
ICAM1 intercellular adhesion molecule 1 hmMSI-H 1,12E+07 0.0002 
MCHR1 melanin concentrating hormone receptor 1 hmMSI-H 1,02E+07 0.0002 
CSF3R colony stimulating factor 3 receptor hmMSI-H 5,69E+05 0.0001 
FPR2 formyl peptide receptor 2 hmMSI-H 5,25E+06 0.0001 
SIGLEC5 sialic acid binding Ig like lectin 5 hmMSI-H 4,77E+06 0.0001 
CLEC4A C-type lectin domain family 4 member A  hmMSI-H 2,37E+06 0.0001 
LILRA3 leukocyte immunoglobulin like receptor A3 hmMSI-H 2,11E+06 0.0001 
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SAC: Serrated adenocarcinoma; hmMSI-H: Colorectal carcinoma showing molecular and histological 
features of microsatellite instability, For simplification purposes, pseudogenes and non-coding RNA were 






Table 4. Immunohistochemical expression of CRCP, CXCL14 and ICAM proteins in 








    
CRCP SAC 22 (55) 18 (45)   
hmMSI-H 10 (50) 10 (50) p=0.4628 
CXCL14 SAC 26 (65) 14 (35)   
hmMSI-H 18 (90) 2 (10) p=0.0353 
ICAM1 SAC 22 (50) 18 (45)   
hmMSI-H 5 (25) 15 (75) p=0.0194 
SAC: Serrated adenocarcinoma; hmMSI-H: Colorectal carcinoma showing molecular and 






















Figure 1. Terms of Gene Ontology Biological Processes differentially represented 
between SAC and hmMSI-H. A. The scatterplot shows the remaining biological 
processes which are differentially expressed between SAC and hMSI-H after the 
redundancy reduction. The graph is represented in a two dimensional space derived by 
applying multidimensional scaling to a matrix of the GO terms’ semantic similarities 
[93]. B. The Tag Cloud displayed words which are differentially represented from the 
SAC vs. hMSI-H comparison with larger and darker letters signifying stronger 
overrepresentation. Underrepresented keywords are not displayed in the Tag Cloud. 
Figure 2.  qPCR results of the mRNA expression of DIO3 and FOXD2 genes in SAC 
and CC tumoral tissue as well as in adjacent non-tumoral specimens. * indicates 
statistical significance. 
Figure 3. Immunohistochemical expression of CRCP, CXCL14 and ICAM1 in normal 
colorectal mucosa. Original 20X magnification. 
Figure 4. Immunohistochemical expression of CRCP, CXCL14 and ICAM1 in serrated 
adenocarcinoma (SAC) and CRC showing histological and molecular features of 
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microsatellite instability (hmMSI-H). Original 20X magnification in all except in 
ICAM1 in SAC (X40). 
 
Supplementary material 
Supplementary material 1. Differentially expressed KEGG pathways and Gene 
Ontology terms in the comparison between SAC and hmMSI-H transcriptomic analysis 
(p-adjusted <0.05)  
Supplementary material 2. Paintomics representations of KEGG pathways A. Cytokine-
cytokine receptor interactions illustrating differences in the contribution of specific 
cytokines and certain cytokine families (mainly, CXC chemokines) in each type of CRC 
subtype. B. Colorectal cancer pathway which shows an over-representation of TGFB1, 
PIK3CG, RAC2 and BIRC5 activities in SAC and those of MAPK10, AXIN2, TCF7 
and mismatch repair proteins MLH1 and MSH2 in hmMSI-H. C. Antigen processing 
and presentation panel illustrates a over-expression in hmMSI-H of genes whose 
proteins are involved in antigen processing through MHC class II and, especially class I. 
Proteins whose gene expression was higher in SAC are depicted in blue boxes those 
higher in hmMSI-H cases are represented in red boxes, the intensity of the colour 
indicating the strength of this difference [92] 
 
 
 
